Stem Cell Transplantation
IIVP salvage regimen yields high response rates before autologous stem cell transplantation
Published in Hematology Week, November 21st, 2005
According to a recently published study from Turkey, "To achieve long-term disease-free survival, high-dose therapy and autologous stem cell transplantation (ASCT) is the current standard approach in patients with relapsed or refractory Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL).
"Because chemosensitivity is a significant factor in determining transplantation eligibility, it is critical to select a salvage chemotherapy regimen that has the potential to induce a high response rate with low nonhematologic toxicity."
"In this...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2005-11-21)
More Articles from Hematology Week
- Coronary Artery Bypass
Hemodilution and surgical hemostasis strongly influence transfusion need - Stem Cell Transplantation
ACE gene D-allele associated with noninfectious pulmonary dysfunction development after HSCT - Stem Cell Transplantation
Glutamine reduces the severity of mucositis in children undergoing HSCT - Surgical Technology
FGV is potentially less time-consuming than standard microsurgical vasovasostomy - Acute Myeloid Leukemia
Phase II study to evaluate Xanafide in combination with ara-C for secondary AML - Adverse Drug Reaction
Patients develop acute liver failure after receiving amoxicillin/clavulanate - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
